Genmab — November 2017
-
Iphone
-
Nice - tak Mads
-
God morgen herfra GC. 24 grader og solen er ved at dukke op bag ved klippen

-
-
this highlights the focus on measuring minimal residual disease (MRD) status -in the CANDOR study, Amgen /Janssen, comparing Kyprolis
(carfilzomib), Darzalex
(daratumumab), and dexamethasone : http://www.businesswire.com/news/home/20171106005325/en/Adaptive-Biotechnologies-Announces-Collaboration-Amgen-Advance-Clinical -
@sukkeralf : Tjaah...., Novod nu 1480 og aktuel kurs 1227, lyder jo helt "hysterisk" hvis det skulle være (en af) årsagerne....
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
